Zoetis Inc. today announced that the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of marketing...
With new label, Dectomax®-CA1 Injectable is the first and only parasite control product with conditional approval to help control economically devastating pest Cochliomyia hominivorax
Zoetis Inc. today announced that the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of marketing...
Zoetis Inc. (NYSE:ZTS) today announced that it has agreed to sell $1.850 billion of senior notes, consisting of $850.0 million aggregate principal amount of 4.150% senior notes due 2028 and $1.0...
Zoetis Inc. (NYSE:ZTS) will participate in the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will...
Bonqat® is the first-and-only FDA-approved product for the alleviation of acute anxiety and fear associated with transportation and veterinary visits in cats
Zoetis Inc. has been selected as a 2024 Catalyst Award recipient for its global initiative, Awareness and Action Drives Impact, that is advancing equity for women and other underrepresented groups...
Zoetis announced the U.S. commercial launch of Librela™(bedinvetmab injection), further demonstrating the company’s advanced leadership in canine innovation and dedication to providing...
Apoquel Chewable, produced by Zoetis, is expected to have comparable efficacy to original Apoquel after the first dose, with a formulation that may enhance medication compliance and improve outcomes...
